Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples